Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MLSS NASDAQ:MODD NASDAQ:NEPH NASDAQ:PAVM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLSSMilestone Scientific$0.64+6.9%$0.61$0.38▼$1.39$50.28M0.93206,315 shs67,868 shsMODDModular Medical$0.72+2.0%$0.72$0.63▼$2.65$38.93M0.1770,957 shs45,138 shsNEPHNephros$4.15-1.2%$3.81$1.36▼$5.00$39.54M1.2351,681 shs137,852 shsPAVMPAVmed$0.47+6.3%$0.53$0.30▼$1.90$10.64M1.09332,273 shs645,085 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLSSMilestone Scientific+6.84%+7.15%+16.36%-29.05%-37.25%MODDModular Medical+2.03%-3.04%-2.77%-11.30%-60.95%NEPHNephros-1.19%+2.47%+28.09%+22.06%+121.33%PAVMPAVmed+6.26%-2.49%-10.66%-25.57%-60.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMLSSMilestone Scientific2.1282 of 5 stars3.53.00.00.00.62.50.0MODDModular Medical0.8425 of 5 stars0.05.00.00.01.31.70.0NEPHNephros2.5195 of 5 stars3.53.00.00.01.00.81.3PAVMPAVmed4.4107 of 5 stars3.55.00.04.31.10.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMLSSMilestone Scientific 3.00Buy$1.2595.31% UpsideMODDModular Medical 0.00N/AN/AN/ANEPHNephros 3.00Buy$5.5032.53% UpsidePAVMPAVmed 3.00Buy$19.003,942.55% UpsideCurrent Analyst Ratings BreakdownLatest PAVM, MODD, MLSS, and NEPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025NEPHNephrosMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $6.006/6/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.50 ➝ $19.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMLSSMilestone Scientific$9.08M5.54N/AN/A$0.11 per share5.82MODDModular MedicalN/AN/AN/AN/A$0.21 per shareN/ANEPHNephros$14.16M3.11$0.02 per share186.40$0.91 per share4.56PAVMPAVmed$2.99M3.45N/AN/A$0.16 per share2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMLSSMilestone Scientific-$6.93M-$0.09N/A∞N/A-52.01%-60.26%-40.23%N/AMODDModular Medical-$18.82M-$0.51N/A∞N/AN/A-185.60%-158.95%11/12/2025 (Estimated)NEPHNephros$70K$0.1234.58∞N/A7.95%14.89%11.64%11/6/2025 (Estimated)PAVMPAVmed$39.79M$1.160.41N/AN/A7,144.80%N/A-20.96%11/12/2025 (Estimated)Latest PAVM, MODD, MLSS, and NEPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q1 2026MODDModular Medical-$0.10-$0.12-$0.02-$0.12$0.20 millionN/A8/7/2025Q2 2025NEPHNephros-$0.0250$0.02+$0.0450$0.02$3.60 million$4.40 million6/20/2025Q4 2025MODDModular Medical-$0.11-$0.12-$0.01-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMLSSMilestone ScientificN/AN/AN/AN/AN/AMODDModular MedicalN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMLSSMilestone ScientificN/A2.851.86MODDModular MedicalN/A4.044.04NEPHNephrosN/A5.414.14PAVMPAVmedN/A0.520.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMLSSMilestone Scientific5.79%MODDModular Medical27.47%NEPHNephros41.10%PAVMPAVmed19.93%Insider OwnershipCompanyInsider OwnershipMLSSMilestone Scientific24.75%MODDModular Medical20.46%NEPHNephros6.70%PAVMPAVmed7.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMLSSMilestone Scientific3078.56 million58.61 millionOptionableMODDModular Medical2055.28 million43.97 millionNot OptionableNEPHNephros3010.60 million9.89 millionNot OptionablePAVMPAVmed9021.93 million20.33 millionOptionablePAVM, MODD, MLSS, and NEPH HeadlinesRecent News About These CompaniesPAVmed enters letter of intent with Duke University to license groundbreaking endoscopic esophageal imaging technologyAugust 28, 2025 | pharmabiz.comPPAVmed plans to license Duke’s oesophageal imaging technologyAugust 28, 2025 | finance.yahoo.comLucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025August 27, 2025 | prnewswire.comPAVmed to license esophageal imaging technology from Duke TechnologyAugust 26, 2025 | msn.comPavmed licenses endoscopic esophageal imaging tech out of DukeAugust 26, 2025 | massdevice.comPAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging TechnologyAugust 26, 2025 | prnewswire.comPAVmed Revenue Jumps 513% in Q2August 14, 2025 | aol.comALucid Diagnostics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comPAVmed Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comLucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | prnewswire.comPAVmed Q2 2025 Earnings PreviewAugust 12, 2025 | msn.comLucid Diagnostics to Participate in Upcoming Investor ConferencesAugust 5, 2025 | prnewswire.comPAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025July 31, 2025 | prnewswire.comPAVmed Inc.: PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleJuly 30, 2025 | finanznachrichten.deLucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025July 30, 2025 | prnewswire.comMolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA TestJuly 16, 2025 | prnewswire.comPAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity FinancingJune 24, 2025 | prnewswire.comPAVmed IncJune 20, 2025 | money.usnews.comMajor California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA TestJune 18, 2025 | prnewswire.comPAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove ...June 4, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimePAVM, MODD, MLSS, and NEPH Company DescriptionsMilestone Scientific NYSE:MLSS$0.64 +0.04 (+6.93%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.64 0.00 (0.00%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.Modular Medical NASDAQ:MODD$0.72 +0.01 (+2.03%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.72 +0.00 (+0.07%) As of 09/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.Nephros NASDAQ:NEPH$4.15 -0.05 (-1.19%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$4.14 -0.02 (-0.36%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.PAVmed NASDAQ:PAVM$0.47 +0.03 (+6.26%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.46 -0.01 (-1.70%) As of 09/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
